Heart safety check for new Weight-Loss drug candidate

NCT ID NCT07697846

Not yet recruiting Knowledge-focused Sponsor: Beijing QL Biopharmaceutical Co.,Ltd Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This phase 1 study investigates whether ZT002 (zovaglutide), an experimental injectable drug given every two weeks, affects the heart's electrical activity in overweight or obese adults. Researchers compare changes in the QT interval—a measure of heart rhythm—between those receiving ZT002 and those receiving a placebo. The trial enrolls about 40 healthy participants aged 18 to 45 with a BMI between 24 and 35.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Zovaglutide (ZT002 injection)
What this could lead to: If safe, this could support further development of ZT002 as a weight-management treatment.
What could go wrong: This is an early, small phase 1 safety study focused on heart effects, not weight loss. It may not show any benefit or could reveal heart risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT , OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVERWEIGHT , OBESITY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing GoBroad Hospital

Beijing, 102200, China

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.